



Food and Drug Administration  
Rockville, MD 20857

MAR 20 2006

Triax Pharmaceuticals, LLC  
Attention: Keith S. Rotenberg, Ph.D.  
20 Commerce Drive, Suite 232  
Cranford, NJ 07016

Docket No: 2005P-0417/CP1

Dear Dr. Rotenberg:

Reference is made to your petition requesting the Food and Drug Administration to declare that tretinoin cream in strengths of 0.0375% and 0.075% are suitable for submission in ANDAs.

FDA has been unable to reach a decision on your requests because they raise complex issues requiring extensive review by Agency officials. We will respond to your petition as soon as we have reached a decision.

Sincerely,

Gary J. Buehler  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research

2005P-0417

LET 1